Multiple fractionation approach for measuring cancer biomarker enrichment in exosomes

Postnova Analytics reports that researchers from the University of Utah (Salt Lake City, USA) have used a novel combination of Asymmetrical Flow Field-Flow Fractionation and Centrifugal Field-Flow Fractionation to measure cancer biomarker enrichment in exosomes.

Multiple fractionation approach for measuring cancer biomarker enrichment in exosomes

Asymmetrical Flow Field-Flow Fractionation (AF4) and Centrifugal Field-Flow Fractionation (CF3) are high resolution separation techniques for fractionation of macromolecules and biological nanoparticles based on their hydrodynamic size (AF4) and mass (CF3).

Exosomes are small extracellular vesicles containing nucleic acid and proteins that show great promise for use in cancer diagnostics and therapeutic applications. As characterization of exosomes had proven challenging with traditional separation techniques due to their inherent heterogeneity and complexity, the Utah researchers turned to a multiple fractionation approach to solve their application challenge.

The goal of the research was to characterize an MCF-7 tumor exosome sample by size using AF4 coupled to multi angle light scattering (MALS), and by mass using CF3. The density of exosomes in CF3 fractions was obtained using hydrodynamic diameter and buoyant mass measured by Nano Tracking Analysis (NTA) and CF3 respectively. Fractions were collected along both size and mass distributions and analyzed by polymerase chain reaction (PCR) for enrichment of the micro-RNA21 (miR21) cancer biomarker.

The heterogenous nature of the exosome sample under study was observed to make batch dynamic light scattering or NTA measurements prone to error, and highlights the usefulness of Field Flow Fractionation techniques for separation and characterization of these complex biologic samples. The study showed that the enrichment of miR21 cancer biomarker was highest in the tumor exosomes with the smallest size, smallest mass, and lowest density.

For a copy of the application report describing this research please visit https://bit.ly/3lAu83A. For further information on Asymmetrical Flow Field-Flow Fractionation (AF4) and Centrifugal Field-Flow Fractionation (CF3) used in this research please contact analysed Postnova Analytics on +49-8191-985-6880 / +44-1885-475007 / +1-801-521-2004 or [email protected].

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Postnova Analytics. (2020, November 27). Multiple fractionation approach for measuring cancer biomarker enrichment in exosomes. News-Medical. Retrieved on December 21, 2024 from https://www.news-medical.net/news/20201127/Multiple-fractionation-approach-for-measuring-cancer-biomarker-enrichment-in-exosomes.aspx.

  • MLA

    Postnova Analytics. "Multiple fractionation approach for measuring cancer biomarker enrichment in exosomes". News-Medical. 21 December 2024. <https://www.news-medical.net/news/20201127/Multiple-fractionation-approach-for-measuring-cancer-biomarker-enrichment-in-exosomes.aspx>.

  • Chicago

    Postnova Analytics. "Multiple fractionation approach for measuring cancer biomarker enrichment in exosomes". News-Medical. https://www.news-medical.net/news/20201127/Multiple-fractionation-approach-for-measuring-cancer-biomarker-enrichment-in-exosomes.aspx. (accessed December 21, 2024).

  • Harvard

    Postnova Analytics. 2020. Multiple fractionation approach for measuring cancer biomarker enrichment in exosomes. News-Medical, viewed 21 December 2024, https://www.news-medical.net/news/20201127/Multiple-fractionation-approach-for-measuring-cancer-biomarker-enrichment-in-exosomes.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
A powerful tool for separation and sizing of virus mixtures